“Buy European” Is Becoming a Healthcare Market Strategy

Europe’s latest agreement on critical medicines deserves more attention from companies looking at the EU market.

The immediate issue is medicine shortages. That matters on its own. Health systems need reliable access to essential medicines. Patients need confidence that the products they depend on will be available. Governments are under pressure to reduce the risk of disruption, especially after several years of pandemic shocks, geopolitical tension, supply-chain strain, and growing concern about overdependence on production outside Europe.

The business strategy side may prove just as important.

The European Parliament’s recent announcement on critical medicines points toward a more assertive European approach to healthcare supply. The agreement is designed to reduce dependency on non-EU countries, strengthen the EU pharmaceutical sector, encourage joint procurement, and support a “Buy European” approach in certain procurement settings.

This is important for healthcare and life sciences companies.

It suggests that Europe is thinking about medicines through a wider strategic lens. Availability, manufacturing capacity, procurement, competitiveness, and supply-chain resilience are moving closer together. A company entering the EU market may begin with regulatory questions, but the commercial strategy has to go further.

Where is the product made? How resilient is the supply chain? How exposed is the company to third-country dependencies? How will procurement bodies view the product? Does the company’s market presence fit the direction European policymakers are trying to move?

Those questions are becoming part of the market-entry conversation earlier than they used to.

That does not mean Europe is closing itself off. It does mean companies should pay closer attention to how policy language is changing.

For years, many companies looked at international growth through familiar categories. Regulatory approval was one workstream. Reimbursement was another. Distribution sat somewhere else. Capital strategy often moved on its own track. That approach is becoming harder to sustain in healthcare.

The EU’s critical medicines agenda shows why.

A medicine shortage is not only a supply problem. It can become a procurement problem, a manufacturing problem, a pricing problem, a political problem, and eventually a market-access problem. Once governments begin treating supply resilience as part of public health policy, companies have to think differently about how they position themselves in the market.

This is especially important for pharmaceutical, medtech, diagnostics, and life sciences companies operating across the U.S., UK, and EU.

In the U.S., companies already have to think through FDA expectations, CMS reimbursement, payer adoption, pricing pressure, investor scrutiny, and the operational realities of commercialization. In Europe, the conversation increasingly includes EU-level pharmaceutical reform, national reimbursement systems, procurement decisions, industrial capacity, and supply-chain resilience. In the UK, life sciences policy is also being tied more directly to economic growth, manufacturing, innovation, and health system transformation.

That creates a different kind of strategy question.

A company may have a strong product and still face problems if the strategy does not account for how the product will be paid for, purchased, distributed, manufactured, and supported. A diagnostics company may need to think about evidence, reimbursement, clinical workflow, and procurement at the same time. A medtech company may need to understand hospital adoption, distribution infrastructure, regulatory expectations, and investor assumptions before choosing how to expand. A pharmaceutical company may need to evaluate whether its manufacturing footprint and supply-chain design fit a market where governments are paying closer attention to resilience.

This is where the “Buy European” language becomes important.

It is not only a phrase about procurement. It is a sign of where healthcare strategy is heading. Europe is placing more value on supply security, industrial capacity, and strategic resilience. Companies do not have to overreact to that, but they should not ignore it.

For U.S. companies looking at Europe, this means the EU market should be viewed as more than another regulatory and commercial opportunity. It is a market shaped by public health priorities, national health systems, EU industrial policy, and growing concern about dependency.

For European companies looking at the U.S., the lesson runs in the other direction. The U.S. opportunity may be large, but it comes with its own policy, reimbursement, pricing, and capital-market pressures.

The practical takeaway is simple: healthcare market entry has to be built earlier and more realistically.

Regulatory clearance or approval remains important, but it does not answer enough of the business questions. The better strategy begins before launch, before fundraising assumptions are locked in, and before companies commit to a market pathway that may not match how the market is actually evolving.

The companies that manage this well will understand the policy environment before it becomes a commercial problem. They will pay attention to how governments are defining resilience. They will think through procurement, supply chains, reimbursement, and market access early enough to make better decisions.

Europe’s critical medicines agreement is an early signal worth watching.

“Buy European” may sound like a procurement preference. For healthcare and life sciences companies, it may also become a market strategy question.